Elekta AB (EKTA.B) AI Stock Analysis

• Market Cap: kr21.70B
• Dividend Yield: 4.23%
• Average Volume (3M): 1.33M
• Price to Earnings (P/E): 74.5
• Beta (1Y): 1.25
• Revenue Growth: -0.90%
• EPS Growth: -70.95%
• Country: SE
• Employees: 4,541
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.64
• Shares Outstanding: 368,587,650
• 10 Day Avg. Volume: 896,136
• 30 Day Avg. Volume: 1,329,676
• PEG Ratio: -0.97
• Price to Book (P/B): 2.13
• Price to Sales (P/S): 1.04
• P/FCF Ratio: 17.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr46.00
• Price Target Upside: -19.01% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: kr56.00 ▼(-1.41% Downside)

Elekta AB's overall stock score is primarily influenced by its stable financial performance and strong cash flow generation. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation, which negatively impacts the score.

Positive Factors

Cash Flow Generation

Strong cash flow growth indicates Elekta's ability to generate cash efficiently, supporting reinvestment in innovation and debt servicing.

Balanced Capital Structure

A balanced capital structure provides Elekta with financial flexibility to pursue strategic investments and withstand economic fluctuations.

Stable Gross Profit Margin

Consistent gross margins reflect effective cost management, allowing Elekta to maintain profitability despite market challenges.

Negative Factors

Negative Revenue Growth

Negative revenue growth suggests potential market challenges or competitive pressures, impacting Elekta's ability to expand its market share.

Declining Profitability Margins

Reduced net profit margins indicate challenges in maintaining profitability, which could affect Elekta's long-term financial health.

Decreased Return on Equity

Lower return on equity reflects reduced profitability from equity investments, potentially impacting investor confidence and future capital raising.

Elekta AB Business Overview & Revenue Model

Company Description

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.

How the Company Makes Money

Elekta generates revenue through multiple channels, primarily from the sale of its radiation therapy systems and software solutions. The company earns substantial income from the sale of its flagship products, such as linear accelerators and brachytherapy systems, which are essential in delivering radiation treatment to cancer patients. Additionally, Elekta provides ongoing maintenance and service contracts, generating recurring revenue over the life cycle of its equipment. The company also benefits from software solutions that support treatment planning and patient management, which are sold as both one-time purchases and subscriptions. Significant partnerships with hospitals, oncology clinics, and research institutions further bolster its revenue streams, as these collaborations often involve long-term contracts and joint ventures aimed at enhancing cancer treatment capabilities. Elekta's focus on innovation and improving patient outcomes ensures its continued relevance and profitability in the evolving healthcare landscape.

Elekta AB Financial Statement Overview

Summary

Elekta AB faces challenges with declining revenue and profitability margins, impacting its income statement. The balance sheet remains stable with moderate leverage, but the return on equity has weakened. Cash flow generation shows improvement, yet the conversion of earnings to cash remains a concern. Overall, the company needs to address revenue growth and profitability to enhance its financial position.

Income Statement

Elekta AB's income statement shows a declining revenue trend with a negative revenue growth rate in the TTM period. The gross profit margin remains stable around 37%, but the net profit margin has significantly decreased to 1.3% in the TTM period, indicating pressure on profitability. EBIT and EBITDA margins have also declined, reflecting operational challenges.

Balance Sheet

The balance sheet of Elekta AB shows a moderate debt-to-equity ratio of 0.86, indicating a balanced leverage position. The return on equity has decreased to 2.3% in the TTM period, suggesting reduced efficiency in generating profits from equity. The equity ratio remains stable, reflecting a solid capital structure.

Cash Flow

Elekta AB's cash flow statement indicates a strong free cash flow growth rate of 50% in the TTM period, showing improvement in cash generation. However, the operating cash flow to net income ratio is low at 0.21, suggesting potential challenges in converting earnings into cash. The free cash flow to net income ratio is moderate at 0.40.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	18.02B	18.12B	16.87B	14.55B	13.76B
Gross Profit	6.75B	6.80B	6.35B	5.44B	5.61B
EBITDA	2.19B	3.29B	2.57B	2.69B	3.07B
Net Income	237.00M	1.30B	943.00M	1.15B	1.25B
Balance Sheet
Total Assets	28.98B	31.41B	29.61B	26.30B	24.84B
Cash, Cash Equivalents and Short-Term Investments	2.96B	2.78B	3.27B	3.07B	4.40B
Total Debt	7.57B	7.25B	6.67B	5.70B	6.24B
Total Liabilities	20.13B	20.63B	19.88B	17.39B	16.65B
Stockholders Equity	8.80B	10.78B	9.73B	8.91B	8.20B
Cash Flow
Free Cash Flow	1.06B	817.00M	400.00M	450.00M	1.71B
Operating Cash Flow	2.63B	2.46B	1.96B	1.86B	2.55B
Investing Cash Flow	-1.67B	-1.92B	-1.61B	-1.65B	-613.00M
Financing Cash Flow	-607.00M	-1.10B	-129.00M	-1.73B	-3.60B

Elekta AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 56.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Positive. The current price of 56.8 is above the 20-day moving average (MA) of 48.97, above the 50-day MA of 48.51, and above the 200-day MA of 48.93, indicating a bullish trend. The MACD of 2.72 indicates Negative momentum. The RSI at 70.16 is Negative, neither overbought nor oversold. The STOCH value of 81.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:EKTA.B.

Elekta AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RAY.B	75 Outperform	$7.70B	35.12	24.30%	1.34%	10.48%	25.19%
CAMX	73 Outperform	$36.48B	46.08	20.86%	―	39.37%	189.04%
VITR	71 Outperform	kr18.98B	43.02	3.34%	0.78%	-1.29%	―
CRAD.B	66 Neutral	€1.11B	47.83	6.93%	―	-5.80%	-65.99%
MCAP	63 Neutral	€8.74B	44.15	15.16%	―	11.30%	-14.49%
EKTA.B	55 Neutral	kr21.70B	74.55	3.08%	4.23%	-0.90%	-70.95%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Elekta AB Corporate Events

Elekta Appoints Nomination Committee for 2026 AGM

Elekta has appointed its Nomination Committee for the 2026 Annual General Meeting, consisting of representatives from major stakeholders including the Fourth Swedish National Pension Fund, Nordea Funds, SEB Funds, and Lannebo Kapitalförvaltning. This strategic move ensures diverse representation and stakeholder engagement in the company’s governance, potentially impacting its strategic direction and reinforcing its commitment to collaborative leadership.

The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta’s 2025 Impact Report Highlights Radiotherapy’s Crucial Role in Cancer Care

Elekta has released its ‘2025 Impact Report’ emphasizing the importance of radiotherapy in modern cancer care. The report advocates for broader adoption and access to advanced radiotherapy, highlighting innovations like adaptive radiotherapy that improve precision and patient outcomes. The report also serves as a resource for cancer patients, showcasing the role of radiotherapy as both a standalone and complementary treatment, and includes patient testimonials demonstrating the benefits of advanced technologies.

The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta Unity Enhances Prostate Cancer Treatment Outcomes

Elekta announced that its MRI-guided adaptive radiation therapy platform, Elekta Unity, has shown to improve the quality of life for men with localized prostate cancer by reducing urinary symptoms. The study, presented at the 2025 ASTRO Annual Meeting, involved 630 patients and demonstrated that adapting radiation therapy to daily anatomical changes can lead to better long-term outcomes. This advancement highlights Elekta’s commitment to enhancing cancer treatment and preserving patients’ quality of life.

The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta Celebrates Two Million Gamma Knife Treatments

Elekta has achieved a significant milestone with over two million patients treated using the Leksell Gamma Knife radiosurgery, a non-invasive alternative to open brain surgery for conditions like brain tumors and neurological disorders. This achievement underscores the impact of Gamma Knife technology in transforming patient care, enhancing quality of life, and maintaining Elekta’s position as a leader in the stereotactic radiosurgery market.

The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK50.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta Announces Executive Management Changes to Strengthen Leadership

Elekta has announced significant changes in its executive management, appointing Klara Eiritz as the new Chief Financial Officer, effective by March 2026, while the current CFO, Chief Commercial Officer, and Chief People Officer will leave the company. These changes are part of a strategic restructuring to enhance leadership capabilities and streamline operations, with the goal of improving commercial execution, responding more effectively to customer needs, and delivering sustainable shareholder value.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK34.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta AB’s 2025 AGM Highlights Strategic Initiatives and Shareholder Returns

Elekta AB held its Annual General Meeting on September 4, 2025, where several key resolutions were passed. The meeting approved a dividend payment, re-elected board members, and authorized share acquisitions and transfers. Additionally, a long-term performance-based share program for 2025 was adopted, focusing on shareholder return, hypofractionation installations, and CO2 reduction, indicating Elekta’s commitment to strategic growth and sustainability.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK34.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

Elekta AB Reports Strong European Sales and Improved Cash Flow in Q1 2025/26

Elekta AB reported a 3% increase in net sales at constant exchange rates for the first quarter of 2025/26, driven by strong performance in Europe. Despite challenges such as FX effects and tariffs impacting margins, the company improved its cash flow significantly by SEK 529 million due to better working capital management. The company achieved several commercial milestones, including FDA clearance for its Leksell Gamma Knife and a significant deal with the University of Texas Southwestern. Elekta expects continued growth in net sales over the fiscal year, despite anticipated challenges in the US and China markets.

The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK53.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.